What are triglyceride-rich lipoprotein (TGRL) remnants? How do TGRL remnants differ from LDL and do these differences make them more atherogenic? Prof. Henry Ginsberg answers these questions in this video.
Subtitles: English, German, Italian & more
This lecture by Henry Ginsberg is part of a series titled "Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities".
This program has been designed to educate physicians and other healthcare professionals with an interest in CV risk on lipid-associated residual risk beyond LDL-c and provide an update of novel findings in basic and clinical science with regard to the association of triglyceride-rich remnant lipoproteins and CV risk. In addition, guidance will be given how to use findings from studies on triglyceride-rich lipoproteins in the treatment of patients in clinical practice.
Prof. Henry Ginsberg, MD - Professor of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Pfizer Inc.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunitiesTargeting triglyceride-rich remnant lipoproteins
Prof. Daniel Gaudet, MD, PhD
- Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunitiesTriglyceride-rich lipoproteins and residual CV risk
Prof. Erik Stroes, MD